echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Pharmaceutical Marketing > Three insights of Jiangsu pharmaceutical centralized procurement: original research, hanging net and centralized procurement, and exclusive varieties

    Three insights of Jiangsu pharmaceutical centralized procurement: original research, hanging net and centralized procurement, and exclusive varieties

    • Last Update: 2022-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 10, Jiangsu officially announced the third batch of drug procurement announcements in the province, confirming that 43 drugs were selected from the drugs that had been listed on the network and had not been evaluated for centralized procurement
    with volume.
     
    Does the third batch of Jiangsu include original drugs?
     
    Here it is said that the draft is not clear, and this time it is clearly included in the catalog of varieties
    .
     
    First of all, it is necessary to define the drugs included in the 43 this time, according to the original text of the announcement, it refers to "drugs that have not passed (including deemed passed) quality and efficacy consistency evaluation"
    .
     
    Note that generic drugs are not said here, if the medical professional background is not considered, but strictly understood from the logical semantics of the text, it refers to the same generic drugs other than those that have not been evaluated (including deemed to be the same), of course, including unevaluated generic drugs and original drugs
    .
     
    On the point of special statement, we are not chewing words, nor are we raising the bar
    .
    It's about sniffing something hard to fathom from the announcement
    .
    This literal meaning is not a good expression
    .
     
    Similarly, it has appeared in the procurement plan of another large province, and people have also indicated in the instructions of the reply company that the original drug
    is included.
    Therefore, on the issue of Jiangsu's inclusion, enterprises should consult the official again to clarify the scope of
    centralized procurement.
     
    The two modes of volume procurement and hanging net have interpenetrated
     
    In addition, it is worth noting that the range of varieties collected this time also has a premise of "hanging the net", which may bring two market problems:
     
    First, varieties that are not listed on the net cannot participate in this collective procurement, of course, if the newly approved drugs are generally new 3/4 class chemicals, they are regarded as evaluations and are not included in this list
    .
    However, some "barefoot" enterprises that want to enter the Jiangsu market through centralized procurement have not passed the evaluation and cut off this road
    .
     
    It can be said that this collective procurement is to manage the stock of the stock varieties already in use in the province, and the word used is to show that not only the price will fall, but also that the province has enough drug range, and there is no need to introduce other varieties that have not been evaluated
    .
    This is "demand-side management"
    .
     
    Second, the entry of net-mounted products into centralized procurement is worth thinking about, which shows that the original two different procurement models have begun to transition and merge.

     
    In the fourth year of centralized procurement, the state has carried out seven batches and eight rounds to include a total of 295 varieties, and the N round of coverage of various provincial and inter-provincial alliances at the local level has also exceeded 3,000 product specifications
    .
     
    Whether it is observed from the scope of a province or the drug structure of a medical institution, commonly used drugs are basically included, and some rising "old drugs and new works" varieties have also been listed
    one by one.
    In the next wave, it is estimated that the "innovative drugs" with the same target will be considered
    .
     
    The seventh batch of national procurement of drugs, through the "one supply and one preparation" system, allows alternative varieties to be listed on the local net, which kicks off the beginning of the "integration" of centralized procurement varieties into the net-hanging plate; On the contrary, local centralized procurement is to continuously replace the varieties of hanging nets with volume procurement
    .
     
    It can be seen that the two procurement models continue to merge, and in the end, most of the commonly used drugs used by provinces, prefectures and cities and medical institutions will complete pricing, hospital access, procurement, use and payment
    through volume procurement.
     
    Exclusive varieties enter the rethinking of volume procurement: there is no forbidden area for collective procurement
     
    Many of the varieties collected in Jiangsu are varieties with a lot of sales, especially some exclusive varieties have been included, which is worthy of serious consideration by enterprises about the true meaning of
    "no forbidden area for centralized procurement".
     
    Although at the local level, the inclusion of exclusive varieties in centralized procurement is nothing new, the large-scale exclusive varieties of chemicals (including dosage form exclusivity) are the first time, which shows that some varieties seem to be in a "safe haven" state and temporary
    .
     
    From the Guangdong Alliance to the Hubei 19 Provinces Traditional Chinese Medicine Alliance, and then to the third batch of centralized procurement in Jiangsu, the setting of centralized procurement rules in various places has become more and more skilled
    .
     
    At the national centralized procurement level, the problem of generic drug substitution of varieties that have been evaluated + achieved sufficient competitive conditions is solved, while the local level focuses on unevaluated varieties with high prices and high procurement amounts, which are ,.
    .
    .
    .
    .
    .
    Well, the words "to achieve full competition" can be omitted here as appropriate, because after several years of cross-coverage by various provincial and inter-provincial alliances, the large varieties that have "reached the state of full competition" have basically been covered, and the price has dropped by at least 60%-80%.

     
    Some exclusive varieties with considerable sales have also been included in the scope of centralized procurement, first Chinese proprietary medicines, and then chemical drugs
    .
     
    According to the law of bidding, exclusivity generally relies on negotiation or negotiation to form a price
    agreed by both parties.
    But centralized procurement is linked to volume and price, and behind the price is to bring the quantity, and for exclusive varieties, isn't this "quantity" the amount that they have worked hard to cultivate in the market before? Their own is still their own, but the price must be limited, and the volume is shrinking, in a word: the volume and price are falling
    .
     
    So, how do such varieties manage their own prices and possible collective procurement risks? This requires advance planning, clear goals, and finding paths and approaches
    .
     
     
    Finally, pay attention to the quote and decryption time
     
    Qualification materials and national lowest price declaration: 9:00 on November 11, 2022 - 17:00 on November 14, 2022
    .
    Mock quote and decryption time: November 24, 2022 (Thursday) 09:00-10:30 Mock quote; 10:35-11:05 Analog decryption
    .
     
    Official offer and decryption date: November 25, 2022 (Friday)
     
    09:00-10:30 Formal offer;
     
    10:35-11:05 Officially declassified
    .
     
    15:30-16:10 Price correction quotation;
     
    16:15-16:45 Price correction decryption
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.